ЭПИГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ РЕГУЛЯЦИИ ГЕННОЙ ЭКСПРЕССИИ В РАЗВИТИИ ПЛОСКОКЛЕТОЧНОГО РАКА ГОЛОВЫ И ШЕИ: ТЕРАПЕВТИЧЕСКИЕ ПЕРСПЕКТИВЫ

Обложка

Цитировать

Полный текст

Об авторах

Р. Б. Самсонов

Научно-исследовательский институт онкологии имени Н. Н. Петрова; Онко-система, ООО; Российский научный центр радиологии и хирургических технологий

Автор, ответственный за переписку.
Email: Rom_207@mail.ru

Роман Борисович Самсонов.

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 194356 Санкт-Петербург, ул. Хошимина, 11/1; 197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70, Rom_207@mail.ru

Россия

З. А. Раджабова

Научно-исследовательский институт онкологии имени Н. Н. Петрова

Email: fake@neicon.ru

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Россия

Ю. В. Чебуркин

Научно-исследовательский институт онкологии имени Н. Н. Петрова; Онко-система, ООО

Email: fake@neicon.ru

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 194356 Санкт-Петербург, ул. Хошимина, 11/1

Россия

В. А. Клюге

Научно-исследовательский институт онкологии имени Н. Н. Петрова

Email: fake@neicon.ru

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Россия

Е. В. Ткаченко

Научно-исследовательский институт онкологии имени Н. Н. Петрова

Email: fake@neicon.ru

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Россия

А. В. Малек

Научно-исследовательский институт онкологии имени Н. Н. Петрова; Онко-система, ООО

Email: fake@neicon.ru

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 194356 Санкт-Петербург, ул. Хошимина, 11/1

Россия

Список литературы

  1. Суконко О.Г., Красный С.А. Алгоритмы диагностики и лечения злокачественных новообразований. Под ред. О.Г. Суконко, С.А. Красного. Минск, 2012. С. 13–30. [Sukonko O.G., Krasnyy S.A. Algorithms of diagnostics and treatment of malignant neoplasms. Eds. by O.G. Sukonko, S.A. Krasnyy. Minsk, 2012. Pp. 13–30. (In Russ.)].
  2. Вельшер Л.З., Матякин Е.Г., Дудицкая Т.К., Поляков Б.И. Онкология. М.: ГЭОТАР-Медиа, 2009. 512 с. [Vel’sher L.Z., Matyakin E.G., Duditskaya T.K., Polyakov B.I. Oncology. Moscow: GEOTAR-Media, 2009. 512 p. (In Russ.)].
  3. Bychkov V.A., Nikitina E.G., Ibragimova M.K. et al. Comprehensive meta-analytical summary on human papillomavirus association with head and neck cancer. Exp Oncol 2016;38(2):68–72.
  4. Jalouli J., Jalouli M.M., Sapkota D. et al. Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res 2012:32(2):571–80.
  5. Кропотов М.А. Общие принципы лечения больных первичным раком головы и шеи. Практическая онкология 2003;4(1):1–8. [Kropotov M.A. General principles of treatment of patients with primary cancer of the head and neck. Prakticheskaya onkologiya = Practical Oncology 2003;4(1): 1–8. (In Russ.)].
  6. Алферов В.С. Органосохраняющие методы лечения рака гортани. М., 1993. 350 c. [Alferov V.S. Organ-preserving methods of treatment of cancer of the larynx. Moscow, 1993. 350 p. (In Russ.)].
  7. Mудунов А.М. Сравнительная оценка эффективности неоадъювантной химиотерапии в комплексном и комбинированном лечении плоскоклеточного рака слизистой оболочки полости рта и ротоглотки. Дис. … канд. мед. наук. М., 2002. 25 с. [Mudunov A.M. Comparative evaluation of neoadjuvant chemotherapy in the complex and combined treatment of squamous cell carcinoma of the mucosa of the oral cavity and oropharynx. Thesis … of candidate of medicine. Moscow, 2002. 25 p. (In Russ.)].
  8. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Злокачественные опухоли 2015;(4s):47–54. [Practical recommendations for drug treatment of tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2015;(4s):47–54. (In Russ.)].
  9. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Eds. by: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, 2016. (In Russ.)].
  10. Ванюшин Б.Ф. Эпигенетика сегодня и завтра. Вавиловский журнал генетики и селекции 2013;17(4/2):805–32. [Vanyushin B.F. Epigenetics today and tomorrow. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Plant Breeding 2013;17(4/2):805–32. (In Russ.)].
  11. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59. doi: 10.1056/NEJMra072067.
  12. Fan C.Y. Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 2004;6(2):152–61.
  13. Bakhtiar S.M., Ali A., Barh D. Epigenetics in head and neck cancer. Methods Mol Biol 2015;1238:751–69. doi: 10.1007/978-1-4939-1804-1_39.
  14. Demokan S., Dalay N. Role of DNA methylation in head and neck cancer. Clin Epigenetics 2011;2(2):123–50. doi: 10.1007/s13148-011-0045-3.
  15. Shridhar K., Walia G.K., Aggarwal A. et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncol 2016;53:1–9. doi: 10.1016/j.oraloncology.2015.11.012.
  16. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420–32.
  17. Chen Y.W., Kao S.Y., Wang H.J., Yang M.H. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer 2013;119(24):4259-67. doi: 10.1002/cncr.28356.
  18. URL: http://www.mirbase.org/.
  19. Gunaratne P.H., Creighton C.J., Watson M., Tennakoon J.B. Large-scale integration of microRNA and gene expression data for identification of enriched microRNA-mRNA associations in biological systems. Methods Mol Biol 2010;667:297–315. doi: 10.1007/978-1-60761-811-9_20.
  20. Gulyaeva L.F., Kushlinskiy N.E. Regulatory mechanisms of microRNA expression. J Transl Med 2016;14(1):143. doi: 10.1186/s12967-016-0893-x.
  21. Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287–314. doi: 10.1146/annurev-pathol-012513-104715.
  22. Courthod G., Franco P., Palermo L. et al. The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 2014;19(5):5704–16. doi: 10.3390/molecules19055704.
  23. John K., Wu J., Lee B.W., Farah C.S. MicroRNAs in Head and Neck Cancer. Int J Dent 2013;2013:650218. doi: 10.1155/2013/650218.
  24. Choi J.D., Lee J.S. Interplay between Epigenetics and Genetics in Cancer. Genomics Inform 2013;11(4):164–73. doi: 10.5808/GI.2013.11.4.164.
  25. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013;153(1):38–55.
  26. Chuang J.C., Jones P.A. Epigenetics and microRNAs. Pediatr Res 2007;61(5 Pt 2):24R–29R.
  27. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010;31(1):27–36.
  28. Baylin S.B., Jones P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. doi: 10.1101/cshperspect.a019505.
  29. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37–50.
  30. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10(5):295–304. doi: 10.1038/nrg2540.
  31. Nan X., Ng H.H., Johnson C.A. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393(6683):386–9.
  32. Fuks F., Hurd P.J., Wolf D. et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278(6):4035–40.
  33. Fuks F., Burgers W.A., Brehm A. et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24(1):88–91.
  34. Sato F., Tsuchiya S. Meltzer S.J., Shimizu K. MicroRNAs and epigenetics. FEBS J 2011;278(10):1598–609. doi: 10.1111/j.1742-4658.2011.08089.x.
  35. Wu L., Mao L., Qi Y. Roles of dicer-like and argonaute proteins in TAS-derived small interfering RNA-triggered DNA methylation. Plant Physiol 2012;160(2):990–9. doi: 10.1104/pp.112.200279.
  36. Wu L., Zhou H., Zhang Q. et al. DNA methylation mediated by a microRNA pathway. Mol Cell 2010;38(3):465–75. doi: 10.1016/j.molcel.2010.03.008.
  37. Wong T.S., Gao W., Chan J.Y. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay. Biomed Res Int 2014;2014:126038. doi: 10.1155/2014/126038.
  38. Entrevan M., Schuettengruber B., Cavalli G. Regulation of Genome Architecture and Function by Polycomb Proteins. Trends Cell Biol 2016;26(7):511–25. doi: 10.1016/j.tcb.2016.04.009.
  39. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10(10):697–708. doi: 10.1038/nrm2763.
  40. Li X., Lin Y., Yang X. et al. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2016;473(4):913–9. doi: 10.1016/j.bbrc.2016.03.150.
  41. Sander S., Bullinger L., Klapproth K. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112(10):4202–12. doi: 10.1182/blood-2008-03-147645.
  42. Varambally S., Cao Q., Mani R.S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322(5908):1695–9. doi: 10.1126/science.1165395.
  43. Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30(3):372–8. doi: 10.1002/stem.1035.
  44. Lundberg M., Renkonen S., Haglund C. et al. Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas. Acta Otolaryngol 2016;136(5):501–5. doi: 10.3109/00016489.2015.1122227.
  45. Hauser B., Zhao Y., Pang X. et al. Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One 2015;10(3):e0116321. doi: 10.1371/journal.pone.0116321.
  46. Yu X., Jiang X., Li H. et al. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev 2014;23(6):576–85. doi: 10.1089/scd.2013.0308.
  47. Swierczynski S., Klieser E., Illig R. et al. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015;15(5):651–64. doi: 10.1517/14712598.2015.1025047.
  48. Le J.M., Squarize C.H., Castilho R.M. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells 2014;6(5):511–25. doi: 10.4252/wjsc.v6.i5.511.
  49. Cho J.H., Dimri M., Dimri G.P. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015;290(16):10555–67. doi: 10.1074/jbc.M114.624361.
  50. Koumangoye R.B., Andl T., Taubenslag K.J. et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer 2015;14:24. doi: 10.1186/s12943-014-0284-y.
  51. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J Clin 2010;60(6):376–92. doi: 10.3322/caac.20085.
  52. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010;19(5):698–711. doi: 10.1016/j.devcel.2010.10.005.
  53. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009;41(1):87–95. doi: 10.1016/j.biocel.2008.09.005.
  54. Roman-Gomez J., Agirre X., Jiménez-Velasco A. et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009;27(8):1316–22. doi: 10.1200/JCO.2008.19.3441.
  55. Bandres E., Agirre X., Bitarte N. et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009;125(11):2737–43. doi: 10.1002/ijc.24638.
  56. Lujambio A., Calin G.A., Villanueva A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105(36):13556–61. doi: 10.1073/pnas.0803055105.
  57. Lehmann U., Hasemeier B., Christgen M. et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008;214(1):17–24.
  58. Zhu D.D., Zhang J., Deng W. et al. Significance of NF-kappaB activation in immortal-ization of nasopharyngeal epithelial cells. Int J Cancer 2016;138(5):1175–85. doi: 10.1002/ijc.29850.
  59. He L., He X., Lim L.P. et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447(7148):1130–4.
  60. Chang T.C., Wentzel E.A., Kent O.A. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26(5):745–52.
  61. Lodygin D., Tarasov V., Epanchintsev A. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7(16):2591–600.
  62. Saito Y., Liang G., Egger G. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9(6):435–43.
  63. Toyota M., Suzuki H., Sasaki Y. et al. Epigenetic silencing of microRNA-34b/c and Bcell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68(11):4123–32. doi: 10.1158/0008-5472.CAN-08-0325.
  64. Jia L.F., Wei S.B., Mitchelson K. et al. miR-34a inhibits migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14. PLoS One 2014;9(9):e108435. doi: 10.1371/journal.pone.0108435.
  65. Cao X., Pfaff S.L., Gage F.H. A functional study of miR-124 in the developing neural tube. Genes Dev 2007;21(5):531–6.
  66. Cheng Y., Li Y., Nian Y. et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 2015;15:306. doi: 10.1186/s12885-015-1303-0.
  67. Peng X.H., Huang H.R., Lu J. et al. MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer 2014;13:186. doi: 10.1186/1476-4598-13-186.
  68. Shin K.H., Pucar A., Kim R.H. et al. Identification of senescence-inducing microRNAs in normal human keratinocytes. Int J Oncol 2011;39(5):1205–11. doi: 10.3892/ijo.2011.1111.
  69. Ando T., Yoshida T., Enomoto S. et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer doi: 10.1002/ijc.24219.
  70. Dang J., Bian Y.Q., Sun J.Y. et al. Micro RNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2013;42(4):315–21. doi: 10.1111/jop.12012.
  71. Kozaki K., Imoto I., Mogi S. et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68(7):2094-105. doi: 10.1158/0008-5472.CAN-07-5194.
  72. Hezova R., Kovarikova A., Srovnal J. et al. Diagnostic and prognostic potential of miR- 21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. Diagn Pathol 2015;10:42.
  73. Wellner U., Schubert J., Burk U.C. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11(12):1487–95.
  74. Wiklund E.D., Bramsen J.B., Hulf T. et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128(6):1327–34. doi: 10.1002/ijc.25461.
  75. Tamagawa S., Beder L.B., Hotomi M. et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 2014;33(4):879–86. doi: 10.3892/ijmm.2014.1625.
  76. Bueno M.J.1, Pérez de Castro I., Gómez de Cedrón M. et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL oncogene expression. Cancer Cell 2008;13(6):496–506. doi: 10.1016/j.ccr.2008.04.018.
  77. Furuta M., Kozaki K.I., Tanaka S. et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31(5):766–76. doi: 10.1093/carcin/bgp250.
  78. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7–17.
  79. Erlich R.B., Rickwood D., Coman W.B. et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009;63(3):381–9. doi: 10.1007/s00280-008-0747-1.
  80. Starkova J., Madzo J., Cario G. et al. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res 2007;13(6):1726–35.
  81. Cinatl J. Jr, Cinatl J., Driever P.H. et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997;8(10):958–63.
  82. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25(4):383–97.
  83. Hrebackova J., Hrabeta J., Eckschlager T. Valproic acid in the complex therapy of malig nant tumors. Curr Drug Targets 2010;11(3):361–79.
  84. Witt D., Burfeind P., von Hardenberg S. et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 2013;34(5):1115–24. doi: 10.1093/carcin/bgt019.
  85. Gan C.P., Hamid S., Hor S.Y. et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012;34(3):344–53. doi: 10.1002/hed.21734.
  86. Lee S.H., Nam H.J., Kang H.J. et al. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. Oncol Rep 2015;34(4):2065–71. doi: 10.3892/or.2015.4145.
  87. Oikawa H., Goh W.W., Lim V.K. et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int 2015;91:62–71. doi: 10.1016/j.neuint.2015.10.010.
  88. Trécul A., Morceau F., Gaigneaux A. et al. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol 2014;92(2):299–311. doi: 10.1016/j.bcp.2014.07.035.
  89. Datta J., Islam M., Dutta S. et al. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 2016;56:32–9. doi: 10.1016/j.oraloncology.2016.02.015.
  90. Datta J., Smith A., Lang J.C. et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cɛ. Oncogene 2012;31(36):4045–53. doi: 10.1038/onc.2011.565.
  91. Piao L., Zhang M., Datta J. et al. Lipidbased nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20(6):1261–9. doi: 10.1038/mt.2012.67.
  92. Jiang L., Liu X., Kolokythas A. et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010;127(3):505–12. doi: 10.1002/ijc.25320.
  93. Song T., Zhang X., Wang C. et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 2011;12(5):1307–11.
  94. Liu X., Wang C., Chen Z. et al. Micro RNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011;440(1):23–31. doi: 10.1042/BJ20111006.
  95. Alhazzazi T.Y., Kamarajan P., Joo N. et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117(8):1670–8. doi: 10.1002/cncr.25676.
  96. Cheng Y., Mai J., Hou T., Ping J. Micro RNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3. Biochem Biophys Res Commun 2016;474(1):57–63. doi: 10.1016/j.bbrc.2016.04.065.
  97. Sengupta S., Muir J.G., Gibson P.R. Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 2006;21(1 Pt 2): 209–18.
  98. Humphreys K.J., Cobiac L., Le Leu R.K. et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013;52(6):459–74. doi: 10.1002/mc.21879.
  99. Hu S., Liu L., Chang E.B. et al. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol Cancer 2015;14:180. doi: 10.1186/s12943-015-0450-x.
  100. Chen H.C., Chen G.H., Chen Y.H. et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009;100(6):1002–11. doi: 10.1038/sj.bjc.6604948.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© , 2016


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.